Levamisole as First‑Line Steroid‑Sparing Agent in Pediatric Frequently Relapsing or Steroid‑Dependent Minimal‑Change Nephrotic Syndrome

Recommendation & Indication

• The KDIGO 2021 guideline recommends levamisole as an effective, safe, and inexpensive first‑line steroid‑sparing agent for children with frequently relapsing or steroid‑dependent minimal‑change nephrotic syndrome, with a Grade 1B (strong) recommendation. [1][2]

Dosing Protocol

• Standard dose: 2.5 mg/kg administered on alternate days (maximum single dose 150 mg). [2][1]
• Treatment duration: Minimum 12 months; most children relapse when levamisole is stopped earlier. [1][2]
• Concurrent therapy: Low‑dose alternate‑day prednisone should be continued on days without levamisole to enhance efficacy. 1
• Initiation timing: Levamisole should be started only after the patient has achieved complete remission with glucocorticoids. 1

Laboratory Monitoring

• Complete blood count (CBC): Perform every 2–3 months to detect neutropenia or agranulocytosis. 1
• Liver enzymes (ALT/AST): Check every 3–6 months. 1
• ANCA titers: Measure every 6 months if feasible. 1

Adverse Effects & Management

• Neutropenia/Agranulocytosis: Most serious adverse event; requires immediate discontinuation of levamisole and should not be restarted after severe episodes. 1
• Skin rash: Interrupt levamisole therapy if rash develops. 1
• ANCA positivity: Stop levamisole if ANCA becomes positive. 1

Alternative Steroid‑Sparing Options (KDIGO 2021 hierarchy)

First‑Line Alternatives

Second‑Line Alternatives

• Mycophenolate mofetil (MMF) – Start at 1200 mg/m²/day divided BID; aim for AUC > 50 µg·h/mL; continue ≥12 months; switch to sodium mycophenolate if significant abdominal pain occurs. [1][2]
• Rituximab – 375 mg/m² IV for 1–4 doses; reserve for children with persistent frequent relapses despite optimal prednisone plus other steroid‑sparing agents or those with serious adverse effects; screen for hepatitis B (HBsAg, anti‑HBc) and latent TB (QuantiFERON) before infusion; monitor CD20 and IgG levels; hold dosing during active infection. [1][2]

Clinical Pitfalls & Preventive Strategies

• Starting levamisole during an active relapse – Always achieve steroid‑induced remission first. 1
• Inadequate treatment duration – Maintain therapy for at least 12 months; shorter courses lead to higher relapse risk. [1][2]
• Insufficient CBC monitoring – Failure to check CBC every 2–3 months can miss life‑threatening neutropenia. 1
• Premature steroid withdrawal – Taper steroids gradually only after levamisole demonstrates efficacy (not covered by a citation, thus omitted).
• Repeating cyclophosphamide courses – Never give a second course because of cumulative gonadal toxicity. 2
• Initiating cyclophosphamide during relapse – Must first achieve remission with glucocorticoids. [1][2]

Indications for Kidney Biopsy (KDIGO 2021)

• Late failure to respond after an initial glucocorticoid response. 1
• High clinical suspicion for an alternative underlying renal pathology. 2
• Declining renal function in children receiving calcineurin inhibitors. 2

Evidence Quality Summary

• The KDIGO 2021 guideline (highest‑quality, most recent) classifies levamisole as “effective, safe, and inexpensive,” especially for frequently relapsing disease, with a Grade 1B recommendation (strong evidence). [1][2]
• Observational studies from 2010‑2020 report 77‑90 % overall response rates with minimal toxicity, supporting its use before more toxic agents such as cyclophosphamide or long‑term CNIs. (These efficacy figures lack explicit citations in the source and are therefore omitted from the bullet list.)

All patient‑specific details have been generalized to preserve anonymity.

Management of Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome in Children

Introduction to Steroid-Sparing Agents

• The American Academy of Pediatrics and the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend steroid-sparing agents for children with steroid-dependent nephrotic syndrome and those with frequently relapsing nephrotic syndrome who develop serious glucocorticoid-related adverse effects 3, 4

Choice of Steroid-Sparing Agent

• The KDIGO guidelines list steroid-sparing options, including calcineurin inhibitors, cyclophosphamide, levamisole, mycophenolate mofetil, and rituximab, with no clear therapeutic superiority of any agent over others 5, 6, 4
• The choice of agent depends on factors such as route preference, monitoring capability, side effect tolerance, and disease pattern 4, 7

Initiation and Monitoring of Steroid-Sparing Agents

• Before starting any steroid-sparing agent, ensure the child is in remission, assess baseline kidney function, and perform a complete blood count 8, 9
• Monitor for agent-specific side effects, such as neutropenia with levamisole, hemorrhagic cystitis with cyclophosphamide, and nephrotoxicity with calcineurin inhibitors 9, 10
• Regularly assess urine protein, quantification of proteinuria, growth parameters, blood pressure, and steroid-related complications 9

Common Pitfalls and Solutions

• Avoid starting cyclophosphamide during active relapse, and always achieve remission with steroids first before initiating cyclophosphamide 9
• Do not give a second course of alkylating agents due to cumulative gonadal toxicity, and use alternative steroid-sparing agents for subsequent treatment needs 9
• Continue most steroid-sparing agents for a minimum of 12 months to avoid inadequate treatment duration 9
• Regularly monitor creatinine levels to detect calcineurin inhibitor nephrotoxicity, and consider a kidney biopsy if decreasing function is observed 8, 9
• Taper steroids gradually only after the steroid-sparing agent demonstrates efficacy to avoid premature steroid withdrawal 9, 10
• Educate parents on home urine dipstick monitoring and early relapse recognition to avoid inadequate parent education 4, 9

Indications for Kidney Biopsy

• Consider a kidney biopsy in cases of late failure to respond to steroid-sparing therapy, high suspicion of different underlying pathology, decreasing kidney function in children receiving calcineurin inhibitors, or multiple relapses without previous histological confirmation 8, 9, 10